Erin Mulvey, MD

Highlights

1
Blood · 2025
EMErin Mulvey
PMID: 40019447DOIFirst author7 citations
2
Future oncology (London, England) · 2025
EMErin Mulvey
PMID: 41117260PMCID: PMC12622355DOIFirst author

Publications

Funding

Active

1 grant

Co-I
Clinical and Translational Science Center - KL2
National Center for Advancing Translational Sciences · 2022–2027
KL2TR002385-06

Completed grants (1)

KP
A Phase I Trial of Tazemetostat Combined with Venetoclax in Patients with Relapsed/Refractory NHL
Lymphoma Research Foundation · 2021–2023Fellowship
LRF 210980-01

Clinical research

Active

3 studies

PI
A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PHASE3 · BeiGene USA · OPEN TO ACCRUAL (as of 2026)
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
NCT06973187
PI
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
PHASE1 · Treeline Biosciences INC · OPEN TO ACCRUAL (as of 2026)
Lymphoma; Lymphoma, Non Hodgkin
NCT07082803
PI
Real-world Outcomes in Patients with Relapsed or Refractory Large B-cell Lymphoma Treated with Epcoritamab
Genmab A/S · OPEN TO ACCRUAL (as of 2025)

Completed & closed trials (5)

PI
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies
PHASE1 · Schrodinger · CLOSED TO ACCRUAL (as of 2026)
Mature B-Cell Neoplasm; Non Hodgkin Lymphoma; DLBCL; Waldenstrom Macroglobulinemia; MALT Lymphoma; Follicular Lymphoma; Pediatric-Type Follicular Lymphoma; IRF4 Gene Rearrangement; EBV-Positive DLBCL, Nos; Burkitt Lymphoma; Plasmablastic Lymphoma; High-grade B-cell Lymphoma; Primary Cutaneous Follicle Center Lymphoma; Primary Effusion Lymphoma; Mantle Cell Lymphoma; DLBCL Germinal Center B-Cell Type; Primary Mediastinal Large B Cell Lymphoma; T-Cell/Histiocyte Rich Lymphoma; ALK-Positive Large B-Cell Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma; Splenic Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Nodal Marginal Zone Lymphoma; HHV8-Positive DLBCL, Nos; Lymphoplasmacytic Lymphoma; Duodenal-Type Follicular Lymphoma
NCT05544019
PI
A Phase II Trial of Tazemetostat Plus Mosunetuzumab in Untreated Follicular Lymphoma
PHASE2 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2026)
Follicular Lymphoma
NCT05994235
PI
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
PHASE3 · Epizyme · CLOSED TO ACCRUAL (as of 2026)
Relapsed/Refractory Follicular Lymphoma; Follicular Lymphoma; Refractory Follicular Lymphoma
NCT04224493
PI
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
PHASE3 · F. Hoffman La-Roche Ltd · CLOSED TO ACCRUAL (as of 2025)
Large B-Cell Lymphoma
NCT06047080
PI
Phase I Trial of Tazemetostat in Combination With Venetoclax in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
PHASE1 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma; Follicular Lymphoma
NCT05618366

Media highlights

Dr Mulvey On Real-World Treatment Discontinuation Data For First-Line BTK Inhibitors In CLL
OncLive · August 5, 2026

External relationships

Advisory/Scientific Board Member

BeOne Medicines USA INC · BMS · Genmab

Other Interest

AbbVie Inc. · BMS

Other

AbbVie Inc. · Eli Lilly and Company · Genentech, Inc.